ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "infliximab"

  • Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting

    Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care

    Denis Choquette1, Michael Starr2, Majed M. Khraishi3, William G. Bensen4, Saeed A. Shaikh5, Jude F. Rodrigues6, Dalton E. Sholter7, Maqbool K. Sheriff8, Julie Vaillancourt9, John S. Sampalis9, Allen J. Lehman10, Susan M. Otawa10, Francois Nantel11 and May Shawi12, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Montreal General Hospital, Montreal, QC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 5Medicine, McMaster University, St Catharines, ON, Canada, 6Rheumatology, Windsor, ON, Canada, 7Rheumatology Associates, Edmonton, AB, Canada, 8Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
  • Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting

    Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System

    Nobunori Takahashi1, Toshihisa Kojima2, Atsushi Kaneko3, Yuji Hirano4 and Naoki Ishiguro1, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 3Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
  • Abstract Number: 2320 • 2013 ACR/ARHP Annual Meeting

    Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis

    Xiaomei Leng1, Weiguo Xiao2, Xiaochun Zhu3, Zhonghui Xu1, Wei Yu1, Jing Lu2, Jiakai Wang2, Xiaoru Xia3, Yongji Li3, Yi Liu4, Yi Zhao4, Honghao Tang5, Dongbao Zhao6, Yeqing Shi6, Huji Xu7, Jun Bao7, Lin Chen7, Ling Lin7, Ling Zhou7, Guoqiang Chen8, Weihong Zhang8 and Yan Zhao1, 1Peking Union Medical College Hospital, Beijing, China, 2The First Hospital of China Medical University, Shenyang, China, 3The First Hospital of Wenzhou Medical College, Wenzhou, China, 4Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, 5West China Hospital of Sichuan University, Chengdu, China, 6Changhai Hospital of Shanghai, Shanghai, China, 7Shanghai Changzheng Hospital, Shanghai, China, 8The First People’s Hospital of Foshan, Foshan, China

     Background/Purpose: To evaluate the efficacy of treatment with infliximab on joint inflammation and bone erosion in rheumatoid arthritis (RA) patients using ultrasonography. Methods: 80 eligible…
  • Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting

    Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO

    Bjorn Gudbjornsson1 and Niels Steen Krogh2, 1Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, 2ZiteLab ApS, Copenhagen, Denmark

    Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
  • Abstract Number: 2033 • 2012 ACR/ARHP Annual Meeting

    Infliximab Is an Effective Therapy in Pediatric Renal Sarcoidosis

    Elisa Wershba1, Laura Lewandowski1, Heather Van Mater2 and C. Egla Rabinovich1, 1Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 2Duke Pediatric Rheumatology, Duke University Medical Center, Durham, NC

    Background/Purpose:   Renal sarcoidosis is an unusual form of a rare multisystem disease, and there is little data to guide therapy. The cytokines implicated in…
  • Abstract Number: 1677 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children

    Matthew L. Stoll1, Anthony B. Morlandt2, Suwat Teerawattanapong2, Daniel Young3, Peter D. Waite4 and Randy Q. Cron1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL, 3Radiology, University of Alabama at Birmingham, Birmingham, AL, 4Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Temporomandibular joint (TMJ) arthritis occurs in as much as 80% of children with juvenile idiopathic arthritis (JIA) and can result in substantial facial deformity.…
  • Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting

    When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry

    Maria Victoria Hernández1, Miguel A. Descalzo2, Juan D. Cañete1, Raimon Sanmarti3 and BIOBADASER Study Group4, 1Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Research Unit. Spanish Society of Rheumatology, Madrid, Spain

    Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
  • Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting

    Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients

    Tsukasa Matsubara1, Satoru Koyano2, Keiko Funahashi2, James E. Middleton2, Takako Miura1, Kosuke Okuda1, Takeshi Nakamura1, Akira Sagawa3, Takeo Sakurai4, Hiroaki Matsuno5, Tomomaro Izumihara6, Eisuke Shono7, Kou Katayama8, Toyomitsu Tsuchida9, Mitsuyoshi Iwahashi10, Tomomi Tsuru11 and Motohiro Oribe12, 1Matsubara Mayflower Hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 4Inoue Hospital, Takasaki, Japan, 5Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 6Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 7Shono Rheumatology Clinic, Fukuoka, Japan, 8Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 9Tsuchida Clinic, Chiba, Japan, 10Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 11PS Clinic, Fukuoka, Japan, 12Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan

    Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…
  • Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting

    The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis

    Hideto Kameda1, Takahiko Kurasawa1, Hayato Nagasawa2, Koichi Amano3 and Tsutomu Takeuchi4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, 3Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
  • Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting

    Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients

    Mathieu Verdet1, Clément Guillou2, Marie-Laure Potier2, Martine Hiron2, Fabienne Jouen3, Olivier Boyer4, Thierry Lequerré5 and Olivier Vittecoq6, 1Rheumatology, Rouen University Hospital, Bois Guillaume, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 3Immunology, Rouen University Hospital, Rouen Cedex, France, 4Immunology, INSERM U905, University of Rouen, Rouen, France, 5Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 6Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France

    Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
  • Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results

    Anjali Patwardhan1, Kelly A. Rouster-Stevens2, Harry L. Gewanter3, Grant D. Syverson4, Renee F. Modica5, Kara M. Schmidt6 and Charles H. Spencer7, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, 3Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, 4Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 5Pediatric Rheumatology, University of Florida, Gainesville, FL, 6Pediatric Rheumatology, Univ of Louisville, Louisville, KY, 7Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders.  Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
  • Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review

    JA Martinez-Lopez Sr.1, J. Graña Sr.2, Santiago Muñoz-Fernandez3, I. Rua-Figueroa4, José M. Pego-Reigosa5, Estíbaliz Loza Sr.6 and SER group for the study of systemic autoimmune diseases7, 1Fundacion Jimenez Diaz, Madrid, Spain, 2Hospital Juan Canalejo, Spain, 3Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, 4Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, 5Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 6Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 7Madrid

    Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology